Tumor-derived extracellular vesicles (EVs) arises as an alternative source of biomarkers in liquid biopsies because cancer cells actively produce EVs enriched in cancer-promoting cellular contents, such as immunosuppressive proteins like PD-L1 and PD1, mRNAs and micro-RNAs, which mediate the dysregulation of both the tumour and the protumor immune responses with a consequent establishment of resistance to immunotherapy [16, 45, 46]. The gene discussed is CD274; the disease is neoplasm.